Stellar science. Focused care.
BRINGING IT ALL TOGETHER FOR YOU.
Stellar science. Focused care.
BRINGING IT ALL TOGETHER FOR YOU.
Stellar science. Focused care.
BRINGING IT ALL TOGETHER FOR YOU.
The StrateGIST program is investigating the safety and effectiveness of an investigational study drug for the treatment of gastrointestinal stromal tumours (GIST). The investigational study drug is designed to be a highly selective and powerful inhibitor of the KIT protein, which is overactive in many people with GIST, causing the cancer cells to grow and accumulate.
For adults with advanced GIST that has progressed while taking imatinib or who cannot tolerate imatinib
The StrateGIST program is investigating the safety and effectiveness of the study drug for the treatment of gastrointestinal stromal tumours (GIST). The investigational study drug is a highly selective and powerful inhibitor of the KIT protein, which is overactive in many people with GIST, causing the cancer cells to grow and accumulate. There are 2 open and enrolling StrateGIST trials.
For adults with advanced GIST that has progressed while taking imatinib or who cannot tolerate imatinib
Talk to your doctor for more information and click on the link below to find a StrateGIST 1 Trial site near you.
Participation in the trial is voluntary and you can choose to leave at any time.